100 related articles for article (PubMed ID: 26475344)
1. CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.
Melchardt T; Hufnagl C; Magnes T; Weiss L; Hutarew G; Neureiter D; Schlattau A; Moser G; Gaggl A; Tränkenschuh W; Greil R; Egle A
BMC Cancer; 2015 Oct; 15():725. PubMed ID: 26475344
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
[TBL] [Abstract][Full Text] [Related]
3. Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study.
Noronha V; Goswami C; Patil S; Joshi A; Patil VM; Murthy V; Arya S; Juvekar S; Goud S; Prabhash K
J Laryngol Otol; 2016 Sep; 130(9):833-42. PubMed ID: 27456399
[TBL] [Abstract][Full Text] [Related]
4. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
[TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
6. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
[TBL] [Abstract][Full Text] [Related]
7. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Strojan P; Grašič Kuhar C; Žumer B; Kadivec M; Karner K; Fajdiga I; Jančar B; Gale N; Poljak M; Kocjan BJ; Zakotnik B
Head Neck; 2014 Nov; 36(11):1555-61. PubMed ID: 24123552
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
[TBL] [Abstract][Full Text] [Related]
9. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
Tishler RB; Posner MR; Norris CM; Mahadevan A; Sullivan C; Goguen L; Wirth LJ; Costello R; Case M; Stowell S; Sammartino D; Busse PM; Haddad RI
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1036-44. PubMed ID: 16682134
[TBL] [Abstract][Full Text] [Related]
10. Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for advanced head and neck cancer.
Billan S; Kaidar-Person O; Atrash F; Doweck I; Haim N; Kuten A; Ronen O
Isr Med Assoc J; 2013 May; 15(5):231-5. PubMed ID: 23841243
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck.
Baghi M; Hambek M; May A; Radeloff A; Gstoettner W; Knecht R
Anticancer Res; 2006; 26(1B):559-63. PubMed ID: 16739320
[TBL] [Abstract][Full Text] [Related]
12. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Haddad R; Tishler R; Wirth L; Norris CM; Goguen L; Sullivan C; O'Donnell L; Li Y; Posner M
Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):678-81. PubMed ID: 16785415
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
[TBL] [Abstract][Full Text] [Related]
14. Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Su YY; Chien CY; Luo SD; Huang TL; Lin WC; Fang FM; Chiu TJ; Chen YH; Lai CC; Hsu CM; Li SH
World J Surg Oncol; 2016 Mar; 14():86. PubMed ID: 27001663
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Posner MR; Hershock DM; Blajman CR; Mickiewicz E; Winquist E; Gorbounova V; Tjulandin S; Shin DM; Cullen K; Ervin TJ; Murphy BA; Raez LE; Cohen RB; Spaulding M; Tishler RB; Roth B; Viroglio Rdel C; Venkatesan V; Romanov I; Agarwala S; Harter KW; Dugan M; Cmelak A; Markoe AM; Read PW; Steinbrenner L; Colevas AD; Norris CM; Haddad RI;
N Engl J Med; 2007 Oct; 357(17):1705-15. PubMed ID: 17960013
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.
Posner MR; Glisson B; Frenette G; Al-Sarraf M; Colevas AD; Norris CM; Seroskie JD; Shin DM; Olivares R; Garay CA
J Clin Oncol; 2001 Feb; 19(4):1096-104. PubMed ID: 11181674
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study.
Fonseca E; Grau JJ; Sastre J; García-Gómez JM; Rueda A; Pastor M; Lara MA; Navalón M; Berrocal A; Tisaire JL; Cruz JJ
Eur J Cancer; 2005 Jun; 41(9):1254-60. PubMed ID: 15908196
[TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
Colevas AD; Busse PM; Norris CM; Fried M; Tishler RB; Poulin M; Fabian RL; Fitzgerald TJ; Dreyfuss A; Peters ES; Adak S; Costello R; Barton JJ; Posner MR
J Clin Oncol; 1998 Apr; 16(4):1331-9. PubMed ID: 9552034
[TBL] [Abstract][Full Text] [Related]
19. Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer.
Lee KC; Lee SH; Lee Y; Park SH; Park J; Cho EK; Shin DB; Lee JH; Kim DY; Kim ST
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):187-91. PubMed ID: 17996392
[TBL] [Abstract][Full Text] [Related]
20. Taxotere, cisplatin, fluorouracil, and leucovorin (TPFL)as induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Kamnerdsupaphon P; Chitapanarux I; Lorvidhaya V; Sumitsawan Y; Tharavichitkul E; Sukthomya V
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1869-73. PubMed ID: 19011334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
